EGFR and osteosarcoma: Similar hybrid nanoparticles were developed by Chen et al., and were conjugated with two ligands, namely CD133 and EGFR aptamers (CL4 and A15 aptamers, respectively), for the eradication of osteosarcoma cells and CSCs.